Rabeprazole

How to order Rabeprazole

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Rabeprazole on Prescriptsy

Rabeprazole is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Rabeprazole sodium is a proton pump inhibitor (PPI) used to treat gastro-oesophageal reflux disease (GORD), duodenal and gastric ulcers, and as part of combination therapy for the eradication of Helicobacter pylori.

It works by irreversibly inhibiting the proton pump (hydrogen-potassium ATPase) on the surface of gastric parietal cells, suppressing both basal and stimulated gastric acid secretion.

Rabeprazole is available as 10 mg and 20 mg gastro-resistant tablets. It is a prescription-only medicine (POM) in the United Kingdom.

Gastro-oesophageal reflux disease is one of the most common gastrointestinal conditions in the UK, affecting an estimated 10% to 20% of the adult population.

It occurs when stomach acid flows back into the oesophagus, causing symptoms such as heartburn (a burning sensation behind the breastbone), acid regurgitation, and difficulty swallowing.

Persistent reflux can damage the oesophageal lining, leading to oesophagitis, stricture formation, Barrett's oesophagus, and, rarely, oesophageal adenocarcinoma.

Proton pump inhibitors are the most effective class of medicines for treating GORD and peptic ulcer disease.

This page provides a comprehensive clinical guide to rabeprazole, including how it works, dosage instructions, side effects, safety warnings, and how to obtain it in the United Kingdom.

Important safety information about rabeprazole

Before reading further, please note these essential safety points.

• Do not take rabeprazole if you are allergic to rabeprazole, other PPIs, or any ingredient in the tablets.
• Seek urgent medical advice if you experience alarm symptoms: unintentional weight loss, difficulty swallowing, vomiting blood, or black tarry stools. These may indicate a serious underlying condition.
• Do not crush, chew, or split the gastro-resistant tablets. Swallow them whole.
• Long-term PPI use should be reviewed at least annually to confirm ongoing need.
• Tell your prescriber about all medicines you are taking, including over-the-counter products and herbal remedies.

Understanding acid-related conditions

The stomach produces hydrochloric acid to aid digestion and to provide a barrier against ingested pathogens.

Acid production is regulated by three main stimuli: histamine (acting via H2 receptors), acetylcholine (via muscarinic M3 receptors), and gastrin (via CCK-B receptors).

All three pathways converge on the proton pump (H+/K+ ATPase) as the final step in acid secretion.

When acid production is excessive or the protective mechanisms of the mucosal lining are impaired, acid-related conditions develop.

Gastro-oesophageal reflux disease occurs when the lower oesophageal sphincter relaxes inappropriately, allowing acidic stomach contents to reflux into the oesophagus.

Risk factors include obesity, hiatus hernia, smoking, alcohol, certain foods (fatty foods, chocolate, citrus, spicy foods), pregnancy, and some medications (calcium channel blockers, nitrates, NSAIDs).

Peptic ulcers (gastric and duodenal) are breaks in the mucosal lining caused by an imbalance between acid-pepsin aggression and mucosal defence.

The two main causes are Helicobacter pylori infection and NSAID use. H. pylori is a Gram-negative bacterium that colonises the gastric mucosa and promotes chronic inflammation and ulceration.

How rabeprazole works

Rabeprazole is a substituted benzimidazole that acts as a prodrug.

After oral administration, it is absorbed from the small intestine (protected from gastric acid degradation by the gastro-resistant coating), enters the systemic circulation, and is distributed to the parietal cells of the stomach.

Within the acidic secretory canaliculi of the parietal cell (pH approximately 1.0), rabeprazole is protonated and converted to an active sulphenamide form.

This active metabolite forms covalent disulphide bonds with cysteine residues on the extracellular (luminal) domain of the H+/K+ ATPase, irreversibly inactivating the pump.

A pharmacological advantage of rabeprazole is its higher pKa value (approximately 5.0) compared with other PPIs (omeprazole pKa approximately 4.0, lansoprazole pKa approximately 3.8).

This means rabeprazole is activated at a less acidic pH, which translates to a faster onset of acid suppression.

Clinical studies have shown that rabeprazole achieves clinically significant acid suppression within the first day of treatment, whereas some other PPIs may take 2 to 3 days.

Another advantage is its metabolism. Although rabeprazole is metabolised by CYP2C19 and CYP3A4, a significant non-enzymatic reduction pathway also contributes to its clearance.

This makes rabeprazole less susceptible to the genetic polymorphisms of CYP2C19 that affect the metabolism of omeprazole and lansoprazole.

Approximately 15% to 20% of Caucasians and up to 20% of East Asian populations are poor metabolisers of CYP2C19, which can cause higher plasma levels and increased effects with omeprazole but has less impact on rabeprazole.

Clinical evidence and UK prescribing guidance

Rabeprazole has been studied extensively in randomised controlled trials for GORD, peptic ulcer disease, and H. pylori eradication.

In GORD trials, rabeprazole 20 mg daily healed erosive oesophagitis in 85% to 92% of patients within 8 weeks, comparable to omeprazole and esomeprazole.

For duodenal ulcer healing, rabeprazole 20 mg daily achieved healing rates above 90% within 4 weeks.

For H. pylori eradication, triple therapy regimens containing rabeprazole, combined with two antibiotics, achieve eradication rates of approximately 80% to 90% when clarithromycin resistance is low.

NICE and PHE guidance recommend first-line triple therapy with a PPI plus two antibiotics for 7 days.

If first-line treatment fails, second-line therapy with a different antibiotic combination should be used, followed by culture-guided therapy if second-line treatment also fails.

NICE clinical guideline CG184 (Gastro-oesophageal reflux disease and dyspepsia in adults) recommends PPIs as the treatment of choice for GORD with oesophagitis and for uninvestigated dyspepsia with GORD symptoms.

It advises using the lowest effective dose for the shortest duration necessary, and reviewing long-term PPI therapy annually.

Rabeprazole compared with other PPIs

Five PPIs are widely available in the UK: omeprazole, lansoprazole, esomeprazole, pantoprazole, and rabeprazole. All work by the same mechanism and have similar efficacy at equivalent doses.

The choice between them is often based on cost, availability, drug interactions, and individual patient factors.

Omeprazole and lansoprazole are the most commonly prescribed PPIs in the UK due to their long track record and low cost.

Esomeprazole (the S-enantiomer of omeprazole) may offer marginal benefits in healing severe oesophagitis.

Rabeprazole's advantages include its faster onset of action and reduced dependence on CYP2C19 metabolism, which may make it a preferred choice for patients taking medicines metabolised by CYP2C19 (such as clopidogrel, although caution is still advised) or for patients of East Asian descent.

Dosage and administration

Rabeprazole gastro-resistant tablets should be swallowed whole with water, not crushed, chewed, or split. Take in the morning, ideally 30 minutes before breakfast, for optimal acid suppression.

GORD: 20 mg once daily for 4 to 8 weeks; maintenance 10 to 20 mg once daily. Duodenal ulcer: 20 mg once daily for 4 weeks.

Gastric ulcer: 20 mg once daily for 6 to 12 weeks. H. pylori eradication: 20 mg twice daily with two antibiotics for 7 days.

Zollinger-Ellison syndrome: starting dose 60 mg once daily, adjusted as needed.

Side effects of rabeprazole

Common side effects

Headache, diarrhoea, nausea, abdominal pain, flatulence, and constipation are the most frequently reported adverse effects. These are generally mild and self-limiting. Dizziness, dry mouth, and skin rash occur less commonly.

Long-term risks

With prolonged use (beyond 1 year), PPIs have been associated with a number of potential risks.

Hypomagnesaemia can develop insidiously and may cause muscle cramps, tremor, cardiac arrhythmias, and seizures.

The MHRA advises measuring magnesium levels before starting long-term PPI therapy and periodically during treatment.

Vitamin B12 deficiency may occur due to reduced absorption of protein-bound B12 in the absence of gastric acid. Iron absorption may also be impaired.

An increased risk of hip, wrist, and spine fractures has been observed in epidemiological studies, particularly in elderly patients on high doses.

Ensuring adequate calcium and vitamin D intake, and reviewing the need for continued PPI therapy, can mitigate this risk.

Clostridium difficile and other enteric infections may be more common in PPI users, as reduced gastric acid impairs the stomach's ability to kill ingested bacteria.

This is particularly relevant in hospital settings and in elderly patients.

Fundic gland polyps (benign gastric polyps) may develop with prolonged use but are usually asymptomatic and often regress after stopping the PPI.

Rare side effects

Interstitial nephritis (kidney inflammation) is a rare but recognised adverse effect of PPIs. Symptoms include malaise, fever, and renal impairment.

Subacute cutaneous lupus erythematosus (SCLE) has been reported rarely; discontinue the PPI if skin lesions develop. Severe allergic reactions (anaphylaxis, Stevens-Johnson syndrome, toxic epidermal necrolysis) are extremely rare.

Seek emergency help by calling 999 for facial or throat swelling, severe skin reactions, or difficulty breathing.

When to seek medical advice

Contact your GP if you experience persistent diarrhoea, unexplained weight loss, difficulty swallowing, or symptoms that do not improve with treatment.

Report alarm symptoms (blood in vomit or stools, progressive dysphagia) urgently, as they may indicate a serious condition requiring investigation.

Report suspected adverse reactions to the MHRA at yellowcard.mhra.gov.uk .

Warnings and precautions

Excluding serious pathology

Alarm symptoms (unintentional weight loss, progressive dysphagia, haematemesis, melaena, persistent vomiting) must be investigated before starting rabeprazole, as PPI therapy can mask the symptoms of gastric malignancy. NICE recommends urgent referral for upper GI endoscopy in patients with alarm symptoms.

Annual review of long-term use

Many patients in the UK take PPIs for longer than clinically necessary.

NICE CG184 recommends reviewing the need for PPI therapy at least once a year and considering stepping down to the lowest effective dose or stopping if the original indication has resolved.

When stopping after prolonged use, rebound acid hypersecretion may cause a temporary worsening of symptoms.

A gradual step-down over 2 to 4 weeks (reducing dose, then switching to alternate-day dosing) may help.

Lifestyle measures (weight management, dietary modification, raising the head of the bed, avoiding late meals) can support successful PPI withdrawal.

Drug interactions

Rabeprazole reduces gastric acidity, which can affect the absorption of drugs requiring an acidic environment: ketoconazole, itraconazole, erlotinib, mycophenolate mofetil, and iron salts.

Atazanavir levels are significantly reduced by PPI co-administration; this combination is not recommended. The interaction between PPIs and clopidogrel has been a subject of significant clinical debate.

Omeprazole is the PPI most strongly implicated in reducing clopidogrel's antiplatelet effect via CYP2C19 inhibition.

Rabeprazole has a lesser effect on CYP2C19, but the MHRA advises caution with any PPI-clopidogrel combination.

High-dose methotrexate levels may be increased by concomitant PPI use; consider temporary PPI withdrawal during high-dose methotrexate treatment.

Special populations

No dose adjustment is needed in renal impairment. Caution is advised in severe hepatic impairment.

Omeprazole is the preferred PPI in pregnancy due to its more extensive safety record.

Rabeprazole should be used in pregnancy only when the benefit outweighs the risk and after discussion with the prescriber.

Lifestyle advice for GORD management

Medication is most effective when combined with lifestyle measures. Maintain a healthy weight, as excess abdominal fat increases intra-abdominal pressure and promotes reflux.

Avoid eating large meals within 3 hours of bedtime. Raise the head of the bed by 10 to 20 cm if night-time reflux is troublesome.

Identify and avoid personal dietary triggers (common ones include fatty or spicy foods, citrus, chocolate, coffee, alcohol, and carbonated drinks).

Stop smoking, as smoking weakens the lower oesophageal sphincter. Reduce alcohol intake. Wear loose-fitting clothing to avoid abdominal compression.

How to get rabeprazole in the UK

Rabeprazole is available on NHS prescription from your GP or an authorised online prescriber registered with the General Pharmaceutical Council (GPhC).

The standard NHS prescription charge in England is 9.90 pounds per item; prescriptions are free in Scotland, Wales, and Northern Ireland.

For occasional heartburn, lower-strength PPIs (omeprazole 10 mg, pantoprazole 20 mg) are available over the counter from pharmacies, but rabeprazole itself is POM only.

Sources

• Rabeprazole sodium 20 mg gastro-resistant tablets, Summary of Product Characteristics (EMC)
• Rabeprazole sodium, British National Formulary (BNF)
• NICE CG184: Gastro-oesophageal reflux disease and dyspepsia in adults
• Heartburn and acid reflux, NHS
• MHRA Yellow Card Scheme